JP6566867B2 - 生きている患者でのアルツハイマー病アッセイ - Google Patents

生きている患者でのアルツハイマー病アッセイ Download PDF

Info

Publication number
JP6566867B2
JP6566867B2 JP2015521863A JP2015521863A JP6566867B2 JP 6566867 B2 JP6566867 B2 JP 6566867B2 JP 2015521863 A JP2015521863 A JP 2015521863A JP 2015521863 A JP2015521863 A JP 2015521863A JP 6566867 B2 JP6566867 B2 JP 6566867B2
Authority
JP
Japan
Prior art keywords
hydrocarbyl
flna
ring
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015521863A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015529802A (ja
JP2015529802A5 (OSRAM
Inventor
ホアウ−ヤン ワン
ホアウ−ヤン ワン
バルビエ リンジー バーンズ
バルビエ リンジー バーンズ
Original Assignee
ペイン セラピューティクス インコーポレイテッド
ペイン セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ペイン セラピューティクス インコーポレイテッド, ペイン セラピューティクス インコーポレイテッド filed Critical ペイン セラピューティクス インコーポレイテッド
Publication of JP2015529802A publication Critical patent/JP2015529802A/ja
Publication of JP2015529802A5 publication Critical patent/JP2015529802A5/ja
Application granted granted Critical
Publication of JP6566867B2 publication Critical patent/JP6566867B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Quinoline Compounds (AREA)
JP2015521863A 2012-07-13 2013-07-12 生きている患者でのアルツハイマー病アッセイ Active JP6566867B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261671445P 2012-07-13 2012-07-13
US61/671,445 2012-07-13
US201361789180P 2013-03-15 2013-03-15
US61/789,180 2013-03-15
PCT/US2013/050368 WO2014012054A1 (en) 2012-07-13 2013-07-12 Alzheimer's disease assay in a living patent

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019139317A Division JP6796168B2 (ja) 2012-07-13 2019-07-30 生きている患者でのアルツハイマー病アッセイ

Publications (3)

Publication Number Publication Date
JP2015529802A JP2015529802A (ja) 2015-10-08
JP2015529802A5 JP2015529802A5 (OSRAM) 2016-09-01
JP6566867B2 true JP6566867B2 (ja) 2019-08-28

Family

ID=49914282

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015521863A Active JP6566867B2 (ja) 2012-07-13 2013-07-12 生きている患者でのアルツハイマー病アッセイ
JP2019139317A Active JP6796168B2 (ja) 2012-07-13 2019-07-30 生きている患者でのアルツハイマー病アッセイ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019139317A Active JP6796168B2 (ja) 2012-07-13 2019-07-30 生きている患者でのアルツハイマー病アッセイ

Country Status (4)

Country Link
US (4) US9354223B2 (OSRAM)
EP (1) EP2872899B1 (OSRAM)
JP (2) JP6566867B2 (OSRAM)
WO (1) WO2014012054A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2872899B1 (en) 2012-07-13 2018-07-11 Pain Therapeutics, Inc. Alzheimer's disease assay in a living patient
WO2014100734A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9611257B2 (en) 2012-12-21 2017-04-04 Epizyme, Inc. PRMT5 inhibitors and uses thereof
WO2014100719A2 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP2935240A1 (en) 2012-12-21 2015-10-28 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US8940726B2 (en) 2012-12-21 2015-01-27 Epizyme, Inc. PRMT5 inhibitors and uses thereof
CA2953572A1 (en) 2014-08-04 2016-02-11 Epizyme, Inc. Prmt5 inhibitors and uses thereof
JP6463162B2 (ja) * 2015-02-10 2019-01-30 キヤノン株式会社 記録制御装置、記録制御方法、及びプログラム
MX2018000298A (es) * 2015-06-26 2018-03-08 Bisio Progetti Spa Capsula de una sola dosis para la preparacion de bebidas.
CN107849017B (zh) 2015-07-31 2021-03-30 辉瑞公司 作为magl抑制剂的1,1,1-三氟-3-羟基丙-2-基氨基甲酸酯衍生物及1,1,1-三氟-4-羟基丁-2-基氨基甲酸酯衍生物
MA44037B1 (fr) 2016-06-06 2020-03-31 Arena Pharm Inc Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
US11040935B2 (en) 2016-10-05 2021-06-22 University of Pittsburgh—of the Commonwealth System of Higher Education Small molecule AMPK activators
AU2018208846A1 (en) 2017-01-20 2019-07-25 Pfizer Inc. 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
WO2018134698A1 (en) 2017-01-23 2018-07-26 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
CA3079819C (en) * 2017-11-06 2023-03-14 Acelot, Inc. Small molecule drugs and related methods for treatment of diseases related to a.beta.42 oligomer formation
US12186307B2 (en) 2019-02-13 2025-01-07 Yale University Methods of treating epilepsy
AU2020224678B2 (en) * 2019-02-21 2024-03-14 Pain Therapeutics, Inc. Solid polymorphs of a FLNA-binding compound and its hydrochloride salts
WO2020178447A1 (en) * 2019-03-06 2020-09-10 LDN Pharma Limited Method for determining efficacy
WO2021050538A1 (en) 2019-09-10 2021-03-18 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods and materials for increasing level of phosphorylated ampk protein
US20220233512A1 (en) * 2020-11-03 2022-07-28 Cassava Sciences, Inc. Inhibiting an immune response mediated by one or more of tlr2, rage, ccr5, cxcr4 and cd4
US20240329056A1 (en) * 2021-07-23 2024-10-03 Cassava Sciences, Inc. Component assay for alzheimer's disease in a living subject

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1220440B (de) 1962-02-14 1966-07-07 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von Derivaten des 1-(o-Bromphenoxy)-2-hydroxy-3-amino-propans und deren Saeureadditionssalzen
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
AU737735B2 (en) * 1997-08-28 2001-08-30 Novartis Ag Lymphocyte function antigen-1 antagonists
PT1083889E (pt) * 1998-06-01 2004-04-30 Ortho Mcneil Pharm Inc Compostos de tetra-hidronaftaleno e sua utilizacao no tratamento de doencas neurodegenerativas
JP2003530542A (ja) * 1999-12-01 2003-10-14 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 神経変性疾患の診断方法
DE10130020A1 (de) 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
AU2003223098A1 (en) 2002-01-14 2003-09-02 Sun Pharmaceutical Industries Limited Novel process for the preparation of substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone
EP1507765A4 (en) 2002-05-03 2006-11-02 Israel Inst Biolog Res METHODS AND COMPOSITIONS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND RELATED COMPOUNDS
US20070149543A1 (en) 2003-01-29 2007-06-28 Stockwell Brent R Agents For Treating Neurodegenerative Diseases
DE102004014304A1 (de) 2004-03-22 2005-10-06 Grünenthal GmbH Substituierte 1,4,8- Triazaspiro[4,5]decan-2-on-Verbindungen
DE102004014296A1 (de) 2004-03-22 2005-10-06 Grünenthal GmbH Substituierte 1,4,8-Triazaspiro[4.5]decan-2-on-Verbindingen
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
JP2009511568A (ja) 2005-10-13 2009-03-19 ワラタ ファーマシューティカルズ， インコーポレイテッド イノシトール誘導体、ならびに異常なタンパク質の折りたたみまたは凝集、あるいはアミロイドの形成、沈着、蓄積または残存を特徴とする疾患の処置におけるその使用
AR057579A1 (es) 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
FR2905009A1 (fr) * 2006-08-18 2008-02-22 Servier Lab Methode de criblage de composes aux proprietes anti-amyloide
US8653068B2 (en) 2009-10-30 2014-02-18 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic
US8614324B2 (en) 2008-10-31 2013-12-24 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic
WO2009059225A2 (en) 2007-11-02 2009-05-07 Pain Therapeutics, Inc. Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin a
CL2008003507A1 (es) * 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
US20100279996A1 (en) 2009-05-04 2010-11-04 Lindsay Burns Barbier Novel analgesic that binds filamin a
US8580808B2 (en) 2009-10-30 2013-11-12 Pain Therapeutic, Inc. Filamin A-binding anti-inflammatory analgesic
US20100279997A1 (en) 2009-05-04 2010-11-04 Lindsay Burns Barbier Analgesic that binds filamin a
WO2010088400A1 (en) 2009-01-28 2010-08-05 Catholic Healthcare West Methods of diagnosing and treating neurodegenerative diseases
US20100280061A1 (en) 2009-05-04 2010-11-04 Lindsay Burns Barbier Novel analgesic that binds filamin a
US8580809B2 (en) 2009-10-30 2013-11-12 Pain Therapeutics, Inc. Filamin A-binding anti-inflammatory analgesic
DK2882428T3 (en) * 2012-07-13 2019-04-15 Pain Therapeutics Inc PROCEDURE TO INHIBIT TAU PHOSPHORIZATION
EP2872899B1 (en) 2012-07-13 2018-07-11 Pain Therapeutics, Inc. Alzheimer's disease assay in a living patient

Also Published As

Publication number Publication date
US20140017698A1 (en) 2014-01-16
JP6796168B2 (ja) 2020-12-02
US11385221B2 (en) 2022-07-12
US9354223B2 (en) 2016-05-31
US20160266149A1 (en) 2016-09-15
WO2014012054A1 (en) 2014-01-16
EP2872899A4 (en) 2015-12-30
EP2872899A1 (en) 2015-05-20
US10222368B2 (en) 2019-03-05
JP2015529802A (ja) 2015-10-08
US9500640B2 (en) 2016-11-22
JP2019206558A (ja) 2019-12-05
US20140017699A1 (en) 2014-01-16
EP2872899B1 (en) 2018-07-11
US20190271686A1 (en) 2019-09-05

Similar Documents

Publication Publication Date Title
JP6566867B2 (ja) 生きている患者でのアルツハイマー病アッセイ
US20210389298A1 (en) Alzheimer's Disease Assay in a Living Patient
KR20230040953A (ko) 치환된 피페리딘 화합물 및 이의 적용례
JP2010502751A (ja) キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
EP2438444A1 (en) Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases
JP6639512B2 (ja) 診断方法、治療剤およびその使用
US20070202547A1 (en) Methods For Detecting Substances Which Bind To The Amyloid Precursor Protein Or Beta Amyloid Fragments, And Binding Compounds
US20210121565A1 (en) Combination Therapy
US20240336620A1 (en) Protein degradation compounds and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160712

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190207

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190703

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190730

R150 Certificate of patent or registration of utility model

Ref document number: 6566867

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250